Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings

FDA Approves More Drugs — And Faster — Than Europe, Study Says

By Marilynn Marchione, AP Chief Medical Writer | April 6, 2017

Share

Contrary to some political claims, the U.S. Food and Drug Administration approved more drugs, and two to three months faster on average, than European regulators did in recent years, new research shows.

“It’s an urban myth” that the FDA is slower than other countries to clear promising treatments for patients, says the agency’s longtime cancer drugs chief, Dr. Richard Pazdur.

He had no role in the approval rate research, which was published Wednesday in the New England Journal of Medicine.

The new research compared how new drugs fared before the FDA and the European Medicines Agency between 2011 and 2015. The FDA approved more drugs than the Europeans — 170 versus 144 — with a median review time of 306 days versus 383 days in Europe.

Reviews were speedier at the FDA for drugs for cancer and blood diseases, but not other maladies, compared to the Europeans. The FDA also moved quicker on so-called orphan drugs, for relatively rare conditions.

This undated image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha. Contrary to some political claims, the FDA actually approved more drugs, including Repatha, and three months faster on average, than European regulators did over the last five years. Three researchers reviewed approvals in the U.S. and Europe and published their results Wednesday, April 5, 2017, in the New England Journal of Medicine. (Robert Dawson/Amgen via AP, File)

The results are similar to a previous analysis that some of the same researchers did for therapies approved between 2001 and 2010. The latest study was done by Dr. Nicholas Downing at Boston’s Brigham and Women’s Hospital, Audrey Zhang at New York University and Dr. Joseph Ross at the Yale School of Medicine.

President Donald Trump has called the FDA’s drug approval process “slow and burdensome,” and his nominee to head the agency, Dr. Scott Gottlieb, has criticized what he calls unnecessary regulations. Gottlieb’s confirmation hearings began on Wednesday.

Some other doctors defend the FDA’s track record.

“We’re the best in the world. Our FDA is great,” says Dr. George Demetri of the Dana-Farber Cancer Institute. He is a board member of the American Association for Cancer Research, and spoke from the group’s annual meeting in Washington, attended by some 20,000 cancer scientists from around the world.


Filed Under: Industry regulations

 

Related Articles Read More >

ids-industrial-camera-manufacturer.sustainability-3
IDS focuses on sustainability in shipping
Part 5: Motion control + MQTT, OPC-UA, and other protocols for cloud services
Facebook CEO Zuckerberg Calls for More Outside Regulation
Musk’s Boring Company Calls it Quits on LA Tunnel, Instead Focuses on Hyperloop

DESIGN GUIDE LIBRARY

“motion

Enews Sign Up

Motion Control Classroom

Design World Digital Edition

cover

Browse the most current issue of Design World and back issues in an easy to use high quality format. Clip, share and download with the leading design engineering magazine today.

EDABoard the Forum for Electronics

Top global problem solving EE forum covering Microcontrollers, DSP, Networking, Analog and Digital Design, RF, Power Electronics, PCB Routing and much more

EDABoard: Forum for electronics

Sponsored Content

  • Global supply needs drive increased manufacturing footprint development
  • How to Increase Rotational Capacity for a Retaining Ring
  • Cordis high resolution electronic proportional pressure controls
  • WAGO’s custom designed interface wiring system making industrial applications easier
  • 10 Reasons to Specify Valve Manifolds
  • Case study: How a 3D-printed tool saved thousands of hours and dollars

Design World Podcasts

May 17, 2022
Another view on additive and the aerospace industry
See More >
Engineering Exchange

The Engineering Exchange is a global educational networking community for engineers.

Connect, share, and learn today »

Design World
  • Advertising
  • About us
  • Contact
  • Manage your Design World Subscription
  • Subscribe
  • Design World Digital Network
  • Engineering White Papers
  • LEAP AWARDS

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings